ClinicalTrials.gg
RecruitingNCT04467671TEVG-2Updated Nov 10, 2026

Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts

A Phase 2 interventional study of Tissue Engineered Vascular Grafts in HLH - Hypoplastic Left Heart Syndrome, DORV and DILV - Double Inlet Left Ventricle, sponsored by Nationwide Children's Hospital. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Nationwide Children's Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hypoplastic Left Heart Syndrome with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Hypoplastic Left Heart Syndrome · United States.

Planned enrollment
18th of 26
24 · median 30
Started
2020
with 1 other
Phase 2
4 of 44
1 open now
Registered
36th of 44
by date

Among the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, this one is the 18th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 36th registered.

Hypoplastic Left Heart Syndrome

67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.

Browse Hypoplastic Left Heart Syndrome studies →

Open to participants now

6 of the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Hypoplastic Left Heart Syndrome studies recruiting now, 3 set no upper age limit and 6 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, or all of them as a file.
02

Study summary

A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.

Read the detailed description

This investigation is a prospective, open-labeled clinical trial determining the safety of the use of tissue engineered vascular grafts as conduits for EC TCPC. Patients will be monitored for adverse events (AE) and serious adverse events (SAE). Special attention will be paid to the incidence of stenosis. We will determine graft-related morbidity and mortality for the second generation TEVGs which will include any post-operative complication such as any aneurismal dilation, stenosis, thromboembolic or infectious event that requires treatment and is thought to be caused by the graft as determined by the investigators and confirmed by the data safety monitoring board. The graft related complication rates will be compared between the first and second generation TEVGs. An interim analysis will be performed to assess the incidence of early (\<6 month) graft-related complications in the first 6 enrolled patients. Safety and tolerability will be assessed through serial imaging, to determine the effect of growth and remodeling on graft performance through echocardiography and 4-dimensional MRI. All appropriate patients requiring EC TCPC who meet study inclusion/exclusion criteria will be evaluated for enrollment in the clinical trial. All enrolled subjects will be required to have follow-up visits at Nationwide Children's Hospital for a minimum of 2 years following implant. After obtaining informed consent for the patient's parents, patients with single ventricle cardiac anomalies will undergo EC TCPC using a tissue engineered conduit. Post-operative care and monitoring will follow an established, standardized, clinical algorithm in which the patient's clinical status including complications and measurements of graft function will be serially evaluated and recorded over a two year period using physical examination, echocardiography, and MRI.

03

Conditions studied

  • HLH - Hypoplastic Left Heart Syndrome
  • DORV
  • DILV - Double Inlet Left Ventricle
  • Mitral Atresia
  • Tricuspid Atresia
  • Unbalanced AV Canal
  • Single-ventricle
  • Heart Defects, Congenital
  • Cardiovascular Abnormalities
  • Cardiovascular Diseases
  • Heart Diseases

Keywords

  • Fontan
  • TEVG
  • Tissue Engineered Vascular Graft
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients will be eligible for inclusion in the study if they meet all of the following criteria.

    1. Patient must be a candidate to undergo an extracardiac total cavopulmonary connection.
    2. Patient and/or legal guardian must voluntarily provide /assent for participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded from participation in the study if they meet any of the following criteria.

    1. Patient has an urgent/emergent operative status.
    2. Patient has acute renal failure or renal insufficiency in the opinion of the investigator
    3. Patient requires a graft less than 12 mm or greater than 24 mm in diameter.
    4. Patient has a pacemaker.
    5. Patient has pulmonary vascular resistance greater than 4 um2 (u=Wood's units)
    6. Patient has abnormal venous drainage (interrupted inferior vena cava [IVC]).
    7. Patient presents with significant atrio-ventricular valve regurgitation that in the opinion of the investigator, makes them ineligible.
    8. Patient has a history of another condition or significant medical problem that, in the opinion of the investigator, precludes compliance with protocol-specified procedures.
    9. Patients taking any medications that in the opinion of the Investigator could interfere with the TEVG, including bisphosphonates (i.e. Clodronate or Zoledronate).
    10. Patient or parent/legal guardian is, in the opinion of the investigator, unable to comply with protocol evaluations.
    11. Preoperative \<11.0 mg/dL at time of patient's pre-admission testing.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Tissue Engineered Vascular Grafts

    Combination Product: Tissue Engineered Vascular Grafts

Interventions

  • Combination productTissue Engineered Vascular Grafts

    Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of TEVG

    Assessed through graft related complications as determined by serial echocardiogram

    Time frame: 2 years

  2. Safety and Tolerability of TEVG

    Assessed through graft related complications as determined by serial MRI

    Time frame: 2 years

  3. Safety and Tolerability of TEVG

    Assessed through adverse events

    Time frame: 2 years

Secondary outcomes

  1. Efficacy of TEVG

    Evaluate graft performance based on MRI

    Time frame: 2 years

  2. Efficacy of TEVG

    Measured graft volume(mL) as determined by MRI

    Time frame: 2 years

  3. Efficacy of TEVG

    Measured graft length (mm) as determined by MRI

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Drews JD, Pepper VK, Best CA, Szafron JM, Cheatham JP, Yates AR, Hor KN, Zbinden JC, Chang YC, Mirhaidari GJM, Ramachandra AB, Miyamoto S, Blum KM, Onwuka EA, Zakko J, Kelly J, Cheatham SL, King N, Reinhardt JW, Sugiura T, Miyachi H, Matsuzaki Y, Breuer J, Heuer ED, West TA, Shoji T, Berman D, Boe BA, Asnes J, Galantowicz M, Matsumura G, Hibino N, Marsden AL, Pober JS, Humphrey JD, Shinoka T, Breuer CK. Spontaneous reversal of stenosis in tissue-engineered vascular grafts. Sci Transl Med. 2020 Apr 1;12(537):eaax6919. doi: 10.1126/scitranslmed.aax6919. PubMed 32238576 ↗
  • Ruiz-Rosado JD, Lee YU, Mahler N, Yi T, Robledo-Avila F, Martinez-Saucedo D, Lee AY, Shoji T, Heuer E, Yates AR, Pober JS, Shinoka T, Partida-Sanchez S, Breuer CK. Angiotensin II receptor I blockade prevents stenosis of tissue engineered vascular grafts. FASEB J. 2018 Jun 15;32(12):fj201800458. doi: 10.1096/fj.201800458. Online ahead of print. PubMed 29906242 ↗
  • Lee YU, Mahler N, Best CA, Tara S, Sugiura T, Lee AY, Yi T, Hibino N, Shinoka T, Breuer C. Rational design of an improved tissue-engineered vascular graft: determining the optimal cell dose and incubation time. Regen Med. 2016 Mar;11(2):159-67. doi: 10.2217/rme.15.85. Epub 2016 Feb 29. PubMed 26925512 ↗
  • Kurobe H, Tara S, Maxfield MW, Rocco KA, Bagi PS, Yi T, Udelsman BV, Dean EW, Khosravi R, Powell HM, Shinoka T, Breuer CK. Comparison of the biological equivalence of two methods for isolating bone marrow mononuclear cells for fabricating tissue-engineered vascular grafts. Tissue Eng Part C Methods. 2015 Jun;21(6):597-604. doi: 10.1089/ten.TEC.2014.0442. Epub 2014 Dec 29. PubMed 25397868 ↗
  • Kurobe H, Maxfield MW, Naito Y, Cleary M, Stacy MR, Solomon D, Rocco KA, Tara S, Lee AY, Sinusas AJ, Snyder EL, Shinoka T, Breuer CK. Comparison of a closed system to a standard open technique for preparing tissue-engineered vascular grafts. Tissue Eng Part C Methods. 2015 Jan;21(1):88-93. doi: 10.1089/ten.TEC.2014.0160. PubMed 24866863 ↗
  • Hibino N, McGillicuddy E, Matsumura G, Ichihara Y, Naito Y, Breuer C, Shinoka T. Late-term results of tissue-engineered vascular grafts in humans. J Thorac Cardiovasc Surg. 2010 Feb;139(2):431-6, 436.e1-2. doi: 10.1016/j.jtcvs.2009.09.057. PubMed 20106404 ↗

Individual participant data

Plan to share: Yes — Biological Samples: We plan to make available representative samples of the bone marrow-derived mononuclear cells and seeded scaffold to a NIH-designated entity (RM Innovation Catalyst) for in depth and independent characterization. Specifically, for each TEVG manufactured, 1 ml of bone marrow-derived mononuclear cells and a 5mm x 5mm section of the seeded scaffold will be sampled, packed, and transported to the RM Innovation Catalyst per their instructions. In addition, copies of the batch record and completed certificate of analysis will be forwarded to the NIH-designated laboratory.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Prior to study initiation, the US FDA will have a comprehensive description of the processes followed to assure the accuracy, reliability, integrity, availability, and authenticity of required records and signatures supporting the data reported in the CSR will be provided to the Agency for confirmation that it will support a regulatory filing for TEVG. Every 6 months throughout the study, data will be shared with RM Innovation Catalyst, with a final locked data set no later than six months prior to the end of the award. Data from our long-term follow up policy will be made available on an annual basis if requested by the RM Innovation Catalyst or the NIH.

Access criteria: De-identified data will be provided to RM Innovation Catalyst. A Clinical Study Report will be submitted to the US FDA following the International Conference on Harmonization E3 Guideline for Industry: Structure and Content of Clinical Study Reports. Summary results of the trial will be submitted to ClinicalTrial.gov within one year of the primary completion date (per regulation and NIH policy). Results of screening tests and subjects participation in the study and ongoing test results will be shared with their primary care physician and/or primary cardiologist if cardiac care is being provided outside of Nationwide Children's Hospital.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2020 (actual). Primary completion is estimated for Dec 2029, 113 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Aug 2026 → Dec 2029 and completion Aug 2027 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2020
First posted
Jul 13, 2020
StartActual
Jul 15, 2020
Primary completionEst.
Dec 2029was Aug 2026
CompletionEst.
Dec 2031was Aug 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Dec 2029
Nov 10, 2026
Study completion
Aug 2027→Dec 2031
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Aug 2026→Dec 2029
    Study completion Aug 2027→Dec 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04467671
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
Jul 15, 2020
Primary completion
Dec 2029 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Samantha Fichtner, BSN, RN
Contact
samantha.fichtner@nationwidechildrens.org
614-355-5764
Christopher Breuer, MD
study chair · Nationwide Children's Hospital
Toshiharu Shinoka, MD/PhD
study chair · Nationwide Children's Hospital
Mark Galantowicz, MD
principal investigator · Nationwide Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion